Neurotherapeutics, published by Springer, is a leading Open Access journal dedicated to the field of neurology and pharmacology, specifically focusing on innovative therapeutic approaches for neurological disorders. With an impressive impact factor and recognized as a prestigious outlet in its domain—ranking Q1 in Neurology (Clinical) and Pharmacology—this journal serves as an invaluable resource for researchers, healthcare professionals, and students aiming to stay updated with the latest advancements in neurotherapeutics. Since its inception in 2007 and now transitioning to Open Access from 2024, Neurotherapeutics enhances accessibility to high-quality research, ensuring that critical findings reach a global audience. Its current Scopus rankings further underscore its significance, placing it within the top echelons of pharmacology and clinical neurology. By fostering a robust platform for the dissemination of pioneering research, Neurotherapeutics plays a crucial role in shaping the future of neurological treatment and care.

Alzheimer's Research & Therapy is a leading peer-reviewed journal published by BMC, dedicated to advancing our understanding of Alzheimer's disease and other neurodegenerative disorders. As an Open Access journal since 2009, it ensures that vital research findings are freely accessible to the global community, facilitating collaboration and innovation in the field. The journal's commitment to quality is evident in its impressive impact factor and its prestigious ranking in the Q1 quartile across multiple categories including Cognitive Neuroscience and Neurology. With a Scopus rank placing it in the top tier of both Neuroscience and Neurology disciplines, Alzheimer's Research & Therapy serves as a crucial platform for researchers, clinicians, and students who seek to contribute to the fight against Alzheimer's and related disorders. The journal covers a wide range of topics and actively encourages submissions that explore therapeutic strategies and innovative research methodologies, enriching the scientific dialogue in this vital area of health.

CNS & Neurological Disorders-Drug Targets is a distinguished journal that focuses on contemporary research and advancements in the realms of neurology, pharmacology, and drug development. Published by Bentham Science Publishers, this journal serves as an essential platform for researchers, professionals, and students interested in the intricate workings of the central nervous system and the evolving strategies to target neurological disorders through pharmacological innovations. With a robust impact factor reflecting its academic relevance, CNS & Neurological Disorders-Drug Targets is categorized in the Q2 quartile for both Medicine (miscellaneous) and Pharmacology, and Q3 for Neuroscience in the 2023 rankings. The journal's Scopus rankings further reinforce its authority, positioning it within the top half of its categories. Operating out of the United Arab Emirates, the journal has been a loyal contributor to the scientific discourse since its inception in 2006 and will continue until at least 2024, ensuring a dynamic channel for the latest findings and reviews in this vital field. As an open-access publication, it prioritizes accessibility, thus fostering a wider impact among scholars and practitioners alike, making it a valuable resource for all stakeholders in neurological and pharmacological research.

EXPERIMENTAL NEUROLOGY is a premier academic journal published by Academic Press Inc, Elsevier Science, focusing on advancements in the fields of Developmental Neuroscience and Neurology. With an impressive Impact Factor and ranked in the Q1 quartile of both categories—positioning it among the top-tier journals—this publication has established itself as a vital resource for researchers, clinicians, and students alike. Since its inception in 1959, it has fostered the dissemination of cutting-edge research and innovative approaches to understanding neurological function and related disorders. While EXPERIMENTAL NEUROLOGY currently operates under a subscription access model, its rich archives and ongoing contributions to the field continue to inspire and inform the next generation of neurobiologists. The journal also boasts a high ranking in Scopus, placing fourth in Developmental Neuroscience and twentieth in Neurology, indicating its robust influence and scholarly significance. For those committed to advancing knowledge in these critical areas, EXPERIMENTAL NEUROLOGY is an indispensable platform for inquiry and discovery.

JOURNAL OF NEUROIMMUNOLOGY is a premier academic journal dedicated to exploring the intricate interactions between the nervous and immune systems. Published by Elsevier, this journal has been at the forefront of neuroimmunology research since its inception in 1981 and continues to disseminate high-quality, peer-reviewed articles that are critical for advancing understanding in the fields of immunology, neurology, and neuroscience. With an impressive impact factor and a Q2 ranking in multiple categories including Neurology and Immunology and Allergy, it serves as an essential resource for researchers, clinicians, and students alike who seek to deepen their knowledge of the neuroimmune landscape. The journal’s rigorous selection process ensures that only the most relevant and impactful research is published, fostering a vibrant academic discourse and facilitating knowledge transfer among professionals in the field. Although the journal is not open access, its contributions to both therapeutic insights and foundational research make it a valuable asset for those committed to the advancement of neuroimmunological science.

Canadian Journal of Neurological Sciences, published by Cambridge University Press, stands as a reputable source of knowledge in the field of neurology, dedicated to advancing research and clinical practice. With an ISSN of 0317-1671 and an E-ISSN of 2057-0155, this journal has been a cornerstone for the exchange of ideas since its inception in 1974 and will continue to cater to the academic community until 2024. Recognized in the top quartile (Q2) in various categories including Medicine (miscellaneous) and Neurology (clinical), its articles engage a broad audience, ranging from established researchers to students seeking to deepen their understanding of neurological sciences. Although the journal is not an open-access publication, it provides vital insights and research findings that contribute significantly to its fields. With a Scopus rank of #183 in clinical neurology and a percentile ranking that reflects its commendable standing, the Canadian Journal of Neurological Sciences is indispensable for those committed to the exploration and treatment of neurological disorders.

NEUROIMMUNOMODULATION is a well-respected journal published by KARGER that focuses on the intricate interactions of the nervous and immune systems. With its ISSN 1021-7401 and E-ISSN 1423-0216, it serves as a vital resource for researchers and professionals interested in neuroimmunology and related fields. The journal has been committed to disseminating high-quality research from its inception in 1994 and continues to thrive, with its scope converged until 2024. Notably, it holds a Q3 ranking in 2023 across diverse categories such as Endocrine and Autonomic Systems, Endocrinology, Immunology, and Neurology, reflecting its significance in the scientific community. Although the journal is not open access, it remains an essential publication for advancing knowledge and fostering collaboration among scholars, making it a noteworthy source of cutting-edge findings in the complex interplay between neural and immune processes.

Multiple Sclerosis and Related Disorders, published by Elsevier Science Ltd, is a leading journal that serves as a vital resource in the field of neurology, particularly focused on multiple sclerosis and its associated conditions. This esteemed journal, which holds a Q1 ranking in Medicine (miscellaneous) and Q2 ranking in both Neurology and Clinical Neurology, delivers high-impact research findings and clinical insights crucial for advancing the understanding and management of multiple sclerosis. With an ISSN of 2211-0348 and an E-ISSN of 2211-0356, it provides valuable content from 2012 to 2024 aimed at researchers, healthcare professionals, and students dedicated to improving patient outcomes and fostering innovative strategies in treatment. Additionally, the journal's presence in the Scopus rankings highlights its relevance and influence in the academic community, ranking 121 out of 400 in Clinical Neurology and 59 out of 192 in Neuroscience. This comprehensive platform encourages the dissemination of cutting-edge knowledge and clinical practices, making it an essential tool for those committed to the field of neurology and related research.

NEUROLOGICAL SCIENCES, published by SPRINGER-VERLAG ITALIA SRL, is a premier journal that has been a cornerstone in the field of neurology and related disciplines since its inception in 1996. With an impressive Q1 ranking in Dermatology and Q2 rankings in Neuroloy (clinical) as well as Psychiatry and Mental Health, this journal consistently delivers high-quality peer-reviewed research that informs and shapes clinical practice. The journal boasts a significant presence on Scopus, positioned in the 89th percentile for Dermatology, 73rd for Psychiatry and Mental Health, and 72nd for Neurology (clinical), reflecting its influential contributions to medical knowledge. Open Access options are available, ensuring that this valuable research is accessible to a wider audience committed to advancing their understanding of neurological sciences. As it converges into future years (2024 and beyond), NEUROLOGICAL SCIENCES aims to continue foster collaboration and innovation amongst researchers, professionals, and students within the neurology and mental health domains, making it an indispensable resource for those dedicated to improving patient outcomes and advancing scholarly dialogue.

Annals of Clinical and Translational Neurology is a premier journal published by WILEY, focusing on the fields of neurology and neuroscience. Since its inception in 2014, it has established itself as an Open Access platform, providing unrestricted access to cutting-edge research to promote scientific collaboration and innovation. With an impressive Impact Factor residing in the top quartile (Q1) for both clinical neurology and miscellaneous neuroscience in 2023, this journal ranks #52 out of 400 in the Neurology category and #22 out of 113 in General Neuroscience, indicating its significant contribution to the field. The journal welcomes submissions that address emerging trends and challenges in translational neurology, aiming to bridge the gap between laboratory research and clinical practice. By disseminating high-quality research and fostering a community of scholars, Annals of Clinical and Translational Neurology plays a vital role in advancing our understanding of neurological disorders and improving patient care worldwide.